Explore the categories so you can find more about your search.

Categorie > Cystic Fibrosis

Increased Cystic Fibrosis Severity And Deficiency In The Protein MBL2 Linked

Categorie : Cystic Fibrosis
Cystic fibrosis (CF), a hereditary disorder causing thick mucous production and frequent lung infections, is associated with a high mortality rate primarily due to lung failure. Although it is known that mutations in the CFTR gene cause the disease, variations in other genes between individuals with ...

read more Cystic fibrosis (CF), a hereditary disorder causing thick mucous production and frequent lung infections, is associated with a high mortality rate primarily due to lung failure. Although it is known that mutations in the CFTR gene cause the disease, variations in other genes between individuals with read more Wed Mar 2008 Wed Mar 2008

Cystic Fibrosis Development Better Understood

Categorie : Cystic Fibrosis
According to a report in the open-access journal PLoSComputational Biology, there is a specific molecularmechanism that could be responsible for the development of cysticfibrosis. The University of North Carolina at Chapel Hill researcherssuggest better understanding of the disease may help to devel ...

read more According to a report in the open-access journal PLoSComputational Biology, there is a specific molecularmechanism that could be responsible for the development of cysticfibrosis. The University of North Carolina at Chapel Hill researcherssuggest better understanding of the disease may help to devel read more Wed Mar 2008 Wed Mar 2008

First Step To Create Cystic Fibrosis Model Using Pigs

Categorie : Cystic Fibrosis
Cystic fibrosis is the most common genetic disease in Caucasians. The median lifespan for those with the disease is 36 years, and lung disease is the major cause of mortality. For years, scientists have studied cystic fibrosis using mice in which the cystic fibrosis gene was altered. However, mice d ...

read more Cystic fibrosis is the most common genetic disease in Caucasians. The median lifespan for those with the disease is 36 years, and lung disease is the major cause of mortality. For years, scientists have studied cystic fibrosis using mice in which the cystic fibrosis gene was altered. However, mice d read more Wed Mar 2008 Wed Mar 2008

Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status For The Treatment Of Cystic Fibrosis

Categorie : Cystic Fibrosis
Mpex Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Mpex orphan drug designation for levofloxacin solution for inhalation for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria ...

read more Mpex Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Mpex orphan drug designation for levofloxacin solution for inhalation for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria read more Wed Mar 2008 Wed Mar 2008

Computer Simulations Point To Key Molecular Basis Of Cystic Fibrosis

Categorie : Cystic Fibrosis
Researchers from the University of North Carolina at Chapel Hill have identified a key molecular mechanism that may account for the development of cystic fibrosis, which about 1 in 3000 children are born with in the US every year. The findings, published February 29 in the open-access journal PLoS C ...

read more Researchers from the University of North Carolina at Chapel Hill have identified a key molecular mechanism that may account for the development of cystic fibrosis, which about 1 in 3000 children are born with in the US every year. The findings, published February 29 in the open-access journal PLoS C read more Wed Mar 2008 Wed Mar 2008

Decline In Cystic Fibrosis Since Introduction Of Prenatal Carrier Screening

Categorie : Cystic Fibrosis
A brief report in the February 28, 2008, New England Journal of Medicine, led by researchers at the New England Newborn Screening Program (NENSP) of the University of Massachusetts Medical School (UMMS), indicates a declining incidence of a genetic disease, providing what may be the first demonstrat ...

read more A brief report in the February 28, 2008, New England Journal of Medicine, led by researchers at the New England Newborn Screening Program (NENSP) of the University of Massachusetts Medical School (UMMS), indicates a declining incidence of a genetic disease, providing what may be the first demonstrat read more Wed Mar 2008 Wed Mar 2008

Aradigm Initiates Phase 2 Study Of Inhaled Liposomal Ciprofloxacin For Cystic Fibrosis

Categorie : Cystic Fibrosis
Aradigm Corporation (OTCBB:ARDM) announced it has initiated a Phase 2 study of its proprietary inhaled liposomal formulation of ciprofloxacin in patients with cystic fibrosis. This safety and efficacy study follows the successful completion of a Phase 1 safety, tolerability and pharmacokinetics tria ...

read more Aradigm Corporation (OTCBB:ARDM) announced it has initiated a Phase 2 study of its proprietary inhaled liposomal formulation of ciprofloxacin in patients with cystic fibrosis. This safety and efficacy study follows the successful completion of a Phase 1 safety, tolerability and pharmacokinetics tria read more Fri Feb 2008 Fri Feb 2008

Gilead Submits New Drug Application To U.S. FDA For Aztreonam Lysine For Inhalation For Cystic Fibrosis

Categorie : Cystic Fibrosis
Gilead Sciences, Inc. (Nasdaq:GILD) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily), an investigational therapy in development for people with cystic fibrosis ( ...

read more Gilead Sciences, Inc. (Nasdaq:GILD) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily), an investigational therapy in development for people with cystic fibrosis ( read more Fri Feb 2008 Fri Feb 2008

New Treatment Guidelines Released By Cystic Fibrosis Foundation

Categorie : Cystic Fibrosis
New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.The guidelines, a result of a two-year review of original research and systematic review literature from 1983 to 2006, were published in the sec ...

read more New clinical standards on the treatment of patients with cystic fibrosis (CF) have been released following an exhaustive review of all available literature.The guidelines, a result of a two-year review of original research and systematic review literature from 1983 to 2006, were published in the sec read more Fri Feb 2008 Fri Feb 2008

UNC To Launch Trial Of Inhaled Saline In Infants With Cystic Fibrosis

Categorie : Cystic Fibrosis
Early next year, researchers at the University of North Carolina at Chapel Hill will begin enrolling infants in a clinical trial to test the effectiveness of inhaled saline as a treatment for cystic fibrosis lung disease. It's a treatment that was proven to work in adults in two earlier studies--one ...

read more Early next year, researchers at the University of North Carolina at Chapel Hill will begin enrolling infants in a clinical trial to test the effectiveness of inhaled saline as a treatment for cystic fibrosis lung disease. It's a treatment that was proven to work in adults in two earlier studies--one read more Fri Feb 2008 Fri Feb 2008

Clues To Gastrointestinal Disease And Cystic Fibrosis Gene Dysfunction Revealed By Study

Categorie : Cystic Fibrosis
A new study by researchers at Hasbro Children's Hospital, the pediatric division of Rhode Island Hospital, and Mount Sinai Hospital, New York, offers new insight into the role that the cystic fibrosis gene plays in the development of gastrointestinal disease.The cystic fibrosis transmembrane conduct ...

read more A new study by researchers at Hasbro Children's Hospital, the pediatric division of Rhode Island Hospital, and Mount Sinai Hospital, New York, offers new insight into the role that the cystic fibrosis gene plays in the development of gastrointestinal disease.The cystic fibrosis transmembrane conduct read more Fri Feb 2008 Fri Feb 2008

Copernicus Receives Milestone Payment From CFFT To Further Development Of Its Non-Viral Gene Therapy For Cystic Fibrosis

Categorie : Cystic Fibrosis
Copernicus Therapeutics, Inc. announced that it received a milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation. This milestone payment is part of a research, development, and commercialization agreement between CFFT an ...

read more Copernicus Therapeutics, Inc. announced that it received a milestone payment from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), a non-profit affiliate of the Cystic Fibrosis Foundation. This milestone payment is part of a research, development, and commercialization agreement between CFFT an read more Fri Feb 2008 Fri Feb 2008

PARI's EFlow Included In Gilead's NDA Submission For Aztreonam Lysine For Inhalation

Categorie : Cystic Fibrosis
PARI Pharma's eFlow electronic nebulizer was included in Gilead's (Nasdaq: GILD) recent New Drug Application (NDA) submittal to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily). Aztreonam lysine for inhalation, delivered ...

read more PARI Pharma's eFlow electronic nebulizer was included in Gilead's (Nasdaq: GILD) recent New Drug Application (NDA) submittal to the U.S. Food and Drug Administration (FDA) for marketing approval of aztreonam lysine for inhalation (75 mg three times daily). Aztreonam lysine for inhalation, delivered read more Fri Feb 2008 Fri Feb 2008

Drug Fights Cystic Fibrosis

Categorie : Cystic Fibrosis
An experimental drug that has proven effective in treating muscular dystrophy also works for cystic fibrosis, according to researchers at the University of Alabama at Birmingham (UAB).The new study is the latest on a compound called PTC124, which helps to "rescue" faulty proteins that lead to illnes ...

read more An experimental drug that has proven effective in treating muscular dystrophy also works for cystic fibrosis, according to researchers at the University of Alabama at Birmingham (UAB).The new study is the latest on a compound called PTC124, which helps to read more Fri Feb 2008 Fri Feb 2008

PTC Therapeutics Announces Publication Of Preclinical Data In PNAS

Categorie : Cystic Fibrosis
PTC Therapeutics, Inc. today announced the publication of new preclinical data in the February 12, 2008 edition of the Proceedings of the National Academy of Sciences (PNAS) which show that PTC124, a novel drug designed to bypass nonsense mutations, was active in a preclinical model of cystic fibros ...

read more PTC Therapeutics, Inc. today announced the publication of new preclinical data in the February 12, 2008 edition of the Proceedings of the National Academy of Sciences (PNAS) which show that PTC124, a novel drug designed to bypass nonsense mutations, was active in a preclinical model of cystic fibros read more Fri Feb 2008 Fri Feb 2008

Rural Equal To City In Cystic Fibrosis Treatment, Australia

Categorie : Cystic Fibrosis
Outreach services for cystic fibrosis (CF) patients in remote areas are as effective as the treatment and management centres in metropolitan areas, according to a study published in the latest Medical Journal of Australia. ...

read more Outreach services for cystic fibrosis (CF) patients in remote areas are as effective as the treatment and management centres in metropolitan areas, according to a study published in the latest Medical Journal of Australia. read more Fri Feb 2008 Fri Feb 2008

Cystic Fibrosis Foundation Reports Upward Trend For Key Health Outcomes

Categorie : Cystic Fibrosis
The Cystic Fibrosis Foundation reported that key indicators of health for people with cystic fibrosis -- including lung function and nutritional status -- are rising nationwide across its accredited care center network. In fact, the outlook for people with CF continues to improve steadily each ...

read more The Cystic Fibrosis Foundation reported that key indicators of health for people with cystic fibrosis -- including lung function and nutritional status -- are rising nationwide across its accredited care center network. In fact, the outlook for people with CF continues to improve steadily each read more Fri Feb 2008 Fri Feb 2008

EPIX Pharmaceuticals Achieves 1.25 Million Dollars Milestone In Collaboration With Cystic Fibrosis Foundation Therapeutics

Categorie : Cystic Fibrosis
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced that it has received a $1.25 million milestone payment from Cystic Fibro ...

read more EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced that it has received a $1.25 million milestone payment from Cystic Fibro read more Fri Feb 2008 Fri Feb 2008

Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects Triolex (He3286) As A Oral Anti-Inflammatory Drug Candidate

Categorie : Cystic Fibrosis
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that Cystic Fibrosis Foundation Therapeutics, Inc, (CFFT), the non-profit drug discovery and development affiliate of the Cystic F ...

read more Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced that Cystic Fibrosis Foundation Therapeutics, Inc, (CFFT), the non-profit drug discovery and development affiliate of the Cystic F read more Fri Feb 2008 Fri Feb 2008

Cystic Fibrosis: License Agreement Boosts Development Of Therapy Against Lung Infections

Categorie : Cystic Fibrosis
An exclusive license for the development and commercialisation of a drug delivery system for lung infections in Cystic Fibrosis patients was signed. As part of the agreement, aRigen Pharmaceuticals Inc., Japan transferred relevant rights to Axentis Pharma AG of Switzerland. The EMEA has ...

read more An exclusive license for the development and commercialisation of a drug delivery system for lung infections in Cystic Fibrosis patients was signed. As part of the agreement, aRigen Pharmaceuticals Inc., Japan transferred relevant rights to Axentis Pharma AG of Switzerland. The EMEA has read more Fri Feb 2008 Fri Feb 2008

1 | 2 | 3 | 4 next >>>



     


Custom Search